Bicara funding, investors and company details

Bicara is an emerging Healthcare - Hospitals and Clinic startup from [●], working in the space of Clinical-stage biotechnology / biopharmaceuticals. Founded by Claire Mazumdar.

Company: Bicara Therapeutics Inc.
Sector: Healthcare - Hospitals and Clinic
Location: [●]
Founders: Claire Mazumdar
Total funding raised: ₹1,372.64 Cr

Company overview

Bicara Therapeutics is a clinical-stage biotechnology company focused on developing novel bifunctional biologic therapies for the treatment of solid tumours. The company’s approach combines the precision of well-validated tumour-targeting antibodies with potent tumour microenvironment modulators to enhance immune response directly within the tumour. By addressing immunosuppressive barriers that limit existing cancer therapies, Bicara aims to improve efficacy and durability of treatment outcomes. Its pipeline is centered on next-generation immuno-oncology biologics designed to deliver targeted, dual-action mechanisms against cancer.

Funding rounds

Latest round (Series C): $ 165.00 Mn (₹1,372.64 Cr.), 2023-12-14. Investors: Braidwell LLP, TPG Life Sciences Innovations, Aisling Capital, Fairmount, Deerfield Management